.png){kind=icon}
Return
Melanoma, Version 2.2016
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2016.0051.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.
Keywords:
ISOLATED LIMB PERFUSION
CARBON-DIOXIDE LASER
CUTANEOUS METASTATIC MELANOMA
COOPERATIVE-ONCOLOGY-GROUP
SENTINEL LYMPH-NODE
STAGE-III MELANOMA
HIGH-RISK MELANOMA
HIGH-DOSE INTERFERON-ALPHA-2B
BACILLUS-CALMETTE-GUERIN
IN-TRANSIT MELANOMA
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations
Cited Papers
No cited papers available